Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
However, Regeneron is constantly looking for its next billion-dollar medicine. And a recent deal it made with a smaller drugmaker helped it beef up its pipeline by acquiring an asset in the hottest therapeutic area right now: weight management. Is Regeneron stock a buy now?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Going up against a giant
Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per the terms of the agreement, Regeneron will pay an upfront amount of $80 million, with potential clinical and regulatory milestones of up to $1.93 billion, in addition to royalties on future sales.
HS-20094 mimics the action of two gut hormones: GLP-1 and GIP. The only approved medicine that does that is Zepbound, the weight loss therapy marketed by Eli Lilly. Zepbound has been a major hit, with incredibly fast-growing sales. Could HS-20094 become similarly successful? The fact that it's in the same class as Zepbound hardly guarantees so, but, according to Regeneron, the medicine has been tested in over 1,000 patients and has shown a potential similar to Zepbound.
It is currently undergoing a Phase 3 clinical trial for obesity and a Phase 2 study for diabetes. Results that are, in fact, on par with Zepbound might jolt Regeneron's share price. This isn't the only attempt by Regeneron to enter the weight loss market. The biotech company has been working on ways to address one drawback of anti-obesity medicines: muscle loss.
It recently announced top-line data in patients taking semaglutide (the active ingredient in the weight loss drug Wegovy) and trevogrumab, a medicine developed to address muscle atrophy. The trial showed that about 35% of weight loss due to semaglutide comes from lean muscle mass, but combining it with trevogrumab could help retain muscle mass while helping patients lose fat instead.
Does this make Regeneron a buy?
If HS-20094 becomes nearly as successful as Zepbound, the $80 million Regeneron paid -- and the $1.93 billion in milestones -- would represent quite the bargain. However, it is too early to celebrate. Despite Regeneron's confidence in this asset, many weight management candidates in the pharmaceutical industry have flopped. That's the nature of developing novel drugs. Most will never reach the market. But the fact that HS-20094 has reached late-stage studies is a good sign.
And at any rate, this move does not make Regeneron less attractive. There are, however, other reasons to buy the stock. Regeneron is mitigating Eylea-related losses with a new, high-definition (HD) version of the medicine, which will continue to attract patients away from the old version due to its more convenient dosing schedule. In the first quarter, total U.S. sales of Eylea and Eylea HD dropped by 26% year over year to $1.04 billion, but revenue from the latter increased by 54% year over year to $307 million.
Eylea HD should also earn some label expansions. Meanwhile, Regeneron's other growth driver is Dupixent, a medicine for eczema. It shares the rights to Dupixent with Sanofi. In the first quarter, Dupixent's sales came in at $3.67 billion, up 19% compared to the year-ago period. The therapy won an indication in treating COPD last year, so expect its revenue to continue moving in the right direction for a while. Regeneron's total sales in the first quarter dropped by 4% year over year to $3 billion.
However, as Eylea HD gains ground, including with new indications, Dupixent continues to make headway, and the biotech earns new products, including those in oncology, it should eventually start growing its sales again. Regeneron's work in weight management could, eventually, contribute to that. So, despite its recent headwinds, the stock still looks attractive.
Should you invest $1,000 in Regeneron Pharmaceuticals right now?
Before you buy stock in Regeneron Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!*
Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
35 minutes ago
- Globe and Mail
What's Wrong With Vertex Pharmaceuticals Stock?
Key Points Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline, which can lead to much more growth in the future. 10 stocks we like better than Vertex Pharmaceuticals › Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth opportunities in the process. This is the type of stock that you might expect to see taking off this year. But that isn't happening. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Instead, the share price of Vertex recently plunged. Excitement around the company has cooled drastically. What's wrong with Vertex Pharmaceuticals, and is it an investment worth buying on the dip, or could there be more trouble ahead for the healthcare stock? Vertex's stock tanks after underwhelming study On Aug. 4, Vertex released its latest quarterly numbers as well as results from a study for VX-993, which is a treatment for acute pain. It was the latter that had the most impact on the stock, and it wasn't good news. Vertex said that the treatment did not meet the primary endpoint in its phase 2 trial, and that it will not move on to further trials related to acute pain. The company has an approved pain medication, Journavx, which regulators approved earlier this year for moderate to severe acute pain. The non-opioid medication was a big win for the company, and investors were hoping VX-993 might be able to build on that success and potentially be a better option for patients. As is often the case with pharma stocks, bad news from a clinical trial can quickly send a stock into a tailspin. Before the recent news came out, Vertex's stock was trading at around $470. As of Tuesday, it had fallen to roughly $396. How the business looks today Despite the setback for Vertex, the business remains in solid shape. In its most recent quarter, which ended on June 30, the company's revenue rose by more than 12% year over year, to just under $3 billion. Vertex is on track to hit its guidance of around $12 billion in revenue for the full year, which would translate into an increase of 9% from the previous year. The company is a leader in cystic fibrosis drugs, and they account for nearly all of its revenue. But Vertex's business is broadening, and there is much more growth on the horizon. Journavx has only recently launched, and it brought in $12 million over the last three months. Casgevy, a gene therapy treatment for sickle cell disease and transfusion-dependent beta-thalassemia, has brought in over $30 million. Both of these products could be blockbusters, generating revenue of more than $1 billion at their respective peaks. What I like most about Vertex's business is its fantastic profit margins. Last quarter, the company's net income totaled $1 billion, which was 35% of its top line. With solid margins, the company can easily grow its profits in the long run, paving the way for a higher valuation. Vertex is a reasonably priced stock with a lot of potential upside According to analyst estimates, Vertex's stock is trading at 22 times its projected future earnings. That's modest given the average S&P 500 stock trades at a forward price-to-earnings multiple of 24. Vertex has the potential to be a tremendous growth stock to own in the long run. While the recent news around VX-993 may be disappointing, it shouldn't dissuade investors from investing in the business. Not every trial will turn out well, and not every drug will be a blockbuster. But with a growing portfolio of drugs and a highly profitable business, Vertex is one of the better healthcare stocks to buy and hold right now. Should you invest $1,000 in Vertex Pharmaceuticals right now? Before you buy stock in Vertex Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025
National Post
3 hours ago
- National Post
Kioxia Achieves Successful Prototyping of 5TB Large-Capacity and 64GB/s High-Bandwidth Flash Memory Module
Article content Enabling Advanced AI Processing at the Edge to Help Boost the Smart Transformation of Industries Article content TOKYO — Kioxia Corporation, a world leader in memory solutions, has successfully developed a prototype of a large-capacity, high-bandwidth flash memory module essential for large-scale artificial intelligence (AI) models. This achievement was made within the 'Post-5G Information and Communication Systems Infrastructure Enhancement R&D Project (JPNP20017)' commissioned by the New Energy and Industrial Technology Development Organization (NEDO), Japan's national research and development agency. This memory module features a large capacity of five terabytes (TB) and a high bandwidth of 64 gigabytes per second (GB/s). Article content Article content To address the trade-off between capacity and bandwidth that has been a challenge with DRAM-based conventional memory modules, Kioxia has developed a new module configuration utilizing daisy-chained connections with beads of flash memories. We have also developed high-speed transceiver technology enabling bandwidths of 128 gigabits per second (Gbps), along with techniques to enhance flash memory performance. These innovations have been effectively applied to both memory controllers and memory modules. Article content The practical application of this memory module is expected to accelerate digital transformation by enabling the adoption of Internet of Things (IoT), Big Data analysis, and advanced AI processing in post-5G/6G Mobile Edge Computing (MEC) servers and other applications. Article content 1. Background In the post-5G/6G era, wireless networks are expected to achieve higher speeds, lower latency, and the ability to connect more devices simultaneously. However, transmitting data to remote cloud servers for processing increases latency across the entire network, including wired networks, making real-time applications difficult. For this reason, there is a need for the widespread adoption of MEC servers that process data closer to users, which is expected to drive digital transformation across a variety of industries. Furthermore, the demand for advanced AI applications, such as generative AI, has been rising in recent years. Alongside the performance improvements of MEC servers, memory modules are also required to have even larger capacity and higher bandwidth. Article content Against this background, Kioxia has focused on enhancing the capacity and bandwidth of memory modules using flash memory for this project. The company has succeeded in developing a prototype memory module with a capacity of 5 TB and a bandwidth of 64 GB/s, and has verified its operability. Article content 2. Achievements of This Project 2.1 Adoption of Daisy-Chain Connections To achieve both large-capacity and high-bandwidth memory modules, Kioxia has adopted a daisy-chain connection with beads of controllers connected to each memory board instead of a bus connection. As a result, the bandwidth is not degraded even when the number of flash memories is increased, and a large capacity beyond the conventional limit is achieved. Article content 2.2 128 Gbps PAM4 1 High-speed, Low-power Transceiver High-speed differential serial signaling is applied to daisy-chain connections between memory controllers instead of parallel signaling to reduce the number of connections, and PAM4 (Pulse Amplitude Modulation with 4 Levels) is utilized to achieve higher bandwidth of 128 Gbps with low-power consumption. Article content Article content 2.3 Technologies Boosting Flash Memory Performance To shorten the read latency of flash memory in memory modules, Kioxia has developed flash prefetch technology, which minimizes the latency by pre-fetching data during sequential accesses, and implemented this in the controller. In addition, memory bandwidth has been increased to 4.0 Gbps by applying low amplitude signaling and distortion correction/suppression technology to the interface between the memory controller and flash memory. Article content 2.4 Memory Controller and Memory Module Prototyping By implementing 128 Gbps PAM4 high-speed, low-power transceivers and technologies boosting flash memory performance, Kioxia has prototyped a memory controller and memory module that uses PCIe® 6.0 (64 Gbps, 8 lanes) as the host interface to the server. The prototyped memory module demonstrated that a capacity of 5TB and a bandwidth of 64GB/s can be realized with less than 40 watts of power consumption. Article content 3. Future Plans In addition to IoT and big data analysis and advanced AI processing at the edge, Kioxia is promoting the early commercialization and practical implementation of the findings from this research, exploiting new market trends such as generative AI. Article content 1 Article content PAM4 (Pulse Amplitude Modulation with 4 Levels): data transmission technique using four voltage levels representing two-bit data. Article content * PCIe is a registered trademark of PCI-SIG. Article content * Company names, product names and service names may be trademarks of third-party companies. Article content * This announcement has been prepared to provide information on our business and does not constitute or form part of an offer or invitation to sell or a solicitation of an offer to buy or subscribe for or otherwise acquire any securities in any jurisdiction or an inducement to engage in investment activity nor shall it form the basis of or be relied on in connection with any contract thereof. Article content * Information in this document, including product prices and specifications, content of services and contact information, is correct on the date of the announcement but is subject to change without prior notice. Article content About Kioxia Article content Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with 'memory' by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems. Article content Article content Article content Article content Article content Contacts Article content
Globe and Mail
4 hours ago
- Globe and Mail
From Smart Farms to Smart Cities: AsiaRF Launches HaLowFly USB Wireless Network Card for Seamless IoT Connectivity in 10 Seconds.
As dawn breaks over a smart farm, automated irrigation systems deliver precise hydration to each crop. At nightfall in the city, intelligent streetlights adjust their brightness to match the flow of pedestrians and traffic. Inside modern factories, robotic arms and sensors work in perfect harmony, driving production efficiency to new heights. Taipei, Taiwan--(Newsfile Corp. - August 20, 2025) - AsiaRF officially launched the HaLowFly USB wireless network card today, allowing various devices to connect to Wi-Fi HaLow networks in just a few seconds without the need for driver installation or complicated settings. Simply plug it in and use it, revolutionizing the complexity and slowness of traditional IoT deployments. Behind these seamless scenes lies the backbone of modern innovation - stable, long-range, low-power IoT connectivity. Now, AsiaRF is setting a new benchmark with the launch of the HaLowFly USB Wi-Fi adapter. Plug-and-Play Wi-Fi HaLow: IoT Without the Wait Unveiled today, the HaLowFly USB Wi-Fi dongle lets devices connect to Wi-Fi HaLow networks in just seconds - with no driver installation, no complex configuration, and no technical headaches. Simply plug it in, and it's ready to work. Its standout feature: true cross-platform compatibility. HaLowFly supports Windows, Linux, Unix, macOS, iOS, and Android. Whether for PCs, tablets, or embedded systems and mobile phones, any device with a USB port can instantly join a long-range IoT kilometer-level wireless coverage, HaLowFly delivers seamless audio and video streaming across vast distances. Built for Harsh Environments Inside, an industrial-grade HaLow radio module powers ultra-low-energy, high-stability connections. On the outside, a durable housing shields it from demanding conditions. Optional high-gain external antennas extend performance even further. From open-air farm monitoring stations to factory automation lines, and from urban safety surveillance to emergency response systems, HaLowFly maintains a secure, stable link - even in heat, humidity, dust, or interference-heavy settings. 10-Second Connection: Efficiency at Its Core First-time setup takes about 10 seconds. Unplug-and-reconnect takes the same. Connection settings can be managed through any web browser - no extra software needed. In contrast to competing solutions requiring special drivers or custom firmware, HaLowFly's instant-connect design reduces deployment time, minimizes maintenance needs, and lowers operational costs. Key Advantages Cross-Platform Compatibility - Works across all major operating systems with one device. True Plug-and-Play - No drivers, no delays, online in seconds. Industrial Reliability - Continuous operation in harsh conditions. Long-Range + Low Power - Broad IoT coverage with minimal energy usage. Pricing & Availability Officially priced at US$139, HaLowFly is now available at a limited-time introductory pre-order price of US$99. AsiaRF's Vision As a pioneer in IoT connectivity, AsiaRF continues to break barriers with innovative technology. The HaLowFly USB Wi-Fi adapter is poised to accelerate global adoption of cross-platform, long-range IoT - powering the future of smart cities, precision agriculture, industrial automation, and beyond. For more information about the product or Wi-Fi HaLow solution, please contact AsiaRF.
